NCT05872763

A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery

Name: Clinical Trial NCT05872763
Creator: Hoffmann-La Roche
Keywords: Carcinoma, Non-Small-Cell Lung, clinical trial

An Observational Cohort Study of Patients With Newly Diagnosed Unresectable Stage IIIB, IIIC, or IV Non-Small-Cell Lung Cancer (NSCLC) in China

Hoffmann-La Roche·ClinicalTrials.govNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Carcinoma, Non-Small-Cell Lung
Study type: Observational

Sponsor & location

Primary sponsor: Hoffmann-La Roche

Timeline & enrollment

Phase: N/A
Start date: Aug 31, 2023
End date: Jun 30, 2025
Enrollment: 1200 participants

Primary outcome

Median Overall Survival (OS),Median weeks on first-line treatment

Summary

This is a multicenter, observational cohort study in China with both primary prospective data collection and retrospective collection of prior treatment information from medical records, which enrolls and follows patients who are newly diagnosed with unresectable stage IIIB/IIIC/IV Non-Small-Cell Lung Cancer (NSCLC) in the selected sites.  This study aims to describe the clinical practice and long-term survival benefits of patients newly diagnosed with unresectable stage IIIB/IIIC/IV NSCLC. The study also seeks to explore the condition of biomarker tests utilization, and to assess potential economic impact on patients in the real world. The safety related events will also be summarized in this study.

ICD-10 classifications

Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05872763
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05872763 through Pure Global AI's free database. This phase not specified trial is sponsored by Hoffmann-La Roche and is currently Not yet recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 1200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.